Table 5. The MTHFR Glu429Ala polymorphism and overall survival in the discovery cohort patients (stratified by treatment with 5-Fluorouracil).

	Treated with 5-FU			Not treated with 5-FU
	Discovery cohort (n = 310)			Discovery cohort (n = 191)
#Variable	HR (95% CI)	p-value	n	HR (95% CI)	p-value	n
MTHFR Glu429Ala		0.206			0.005
AC vs AA	0.88 (0.61–1.28)	0.514	143 vs 140	2.47 (1.15–5.27)	0.020	85 vs 92
CC vs AA	1.51 (0.85–2.68)	0.161	27 vs 140	6.08 (1.95–18.93)	0.002	14 vs 92
Age	1.02 (1.00–1.04)	0.132		1.09 (1.04–1.14)	0.001
Stage		<0.001			<0.001
II vs I	2.56 (0.35–18.81)	0.356	104 vs 7	0.67 (0.31–1.41)	0.289	89 vs 87
III vs I	2.58 (0.36–18.76)	0.349	154 vs 7	7.70 (2.76–21.48)	<0.001	10 vs 87
IV vs I	15.84 (2.16–115.98)	0.007	45 vs 7	2.98 (0.83–10.66)	0.093	5 vs 87
MSI-H vs MSI-L/MSS	0.08 (0.01–0.57)	0.012	23 vs 287	0.53 (0.16–1.82)	0.315	32 vs 159

5-FU: 5-fluorouracil, CI: confidence interval, HR: hazard ratio, n: number of patients, vs: versus.

#The referent categories are underlined. Please note that reflecting the small numbers of patients, the CIs for the effect estimate in stage IV patients are quite wide and should not be interpreted as an accurate estimation.